DNA Ploidy and S-Phase Fraction in Melanoma Prognosis
Author Information
Author(s): T. Muhonen, S. Pyrhdnen, A. Laasonen, S. Asko-Seljavaara, K. Franssila
Primary Institution: Helsinki University Central Hospital
Hypothesis
Does DNA aneuploidy and low S-phase fraction predict better survival in metastatic melanoma?
Conclusion
DNA aneuploidy and low S-phase fraction are associated with longer survival in metastatic melanoma patients.
Supporting Evidence
- 67% of tumors were DNA aneuploid, which correlated with longer survival.
- Patients with DNA aneuploid tumors had a median survival of 28 months compared to 16 months for DNA diploid tumors.
- Low S-phase fraction was associated with better prognosis.
Takeaway
This study found that patients with a certain type of cancer called melanoma do better if their cancer cells have an abnormal amount of DNA and a low growth rate.
Methodology
Flow cytometric analysis was used to assess DNA ploidy and S-phase fraction in tumor samples from patients with metastatic melanoma.
Potential Biases
The decision to treat patients systemically was not based on DNA ploidy, which may introduce bias.
Limitations
The study's findings may not apply to all melanoma patients due to the specific treatment protocols used.
Participant Demographics
58 male and 37 female patients with a mean age of 57 years.
Statistical Information
P-Value
p<0.0002
Confidence Interval
95% confidence limits for median survival time reported
Statistical Significance
p<0.002
Want to read the original?
Access the complete publication on the publisher's website